AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine

{
  "signal_id": "ae38799d-965f-8b6a-654e-89d847832a85",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-09-10T12:55:00+00:00",
  "company": {
    "name": "AbbVie",
    "domain": "abbvie.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/abbvie-extends-migraine-leadership-with-positive-phase-3-atogepant-results-in-menstrual-migraine-302874436.html",
    "title": "AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine",
    "excerpt": "NORTH CHICAGO, Ill. , Sept. 10, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced positive topline results from the Phase 3 LUNA study, which evaluated atogepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, for the preventive treatment of menstrual migraine in adults. 1 These results reinforce AbbVie's scientific expertise in migraine and its focus on advancing solutions for people living with complex and disabling migraine attacks. \"These positive Phase 3 LUNA results represent an important advancement for people living with menstrual migraine, with atogepant demonstrating superior efficacy versus placebo across the primary endpoint and all eight ranked secondary endpoints,\" said Primal Kaur, M.D., senior vice president, global development of immunology, neuroscience, eye care and specialty at AbbVie. \"Menstrual migraine attacks can be severe, long lasting and disruptive to daily life. These data bring us closer to our goal of bringing a potential treatment option for women living with this debilitating disease.\" Atogepant Met Primary and All Ranked Secondary Endpoints in Phase 3 LUNA The study evaluated atogepant taken for seven consecutive days starting three days before the onset of menses over three menstrual cycles. 1 Atogepant met the primary endpoint, demonstrating a greater reduction than placebo in migraine days during the perimenstrual...",
    "product": "atogepant",
    "summary": "AbbVie announced positive topline results from its Phase 3 LUNA study for atogepant, a preventive treatment for menstrual migraine in adults, which met its primary endpoint and all eight ranked secondary endpoints.",
    "location": "North Chicago, Illinois, USA",
    "planning": false,
    "confidence": 0.95,
    "product_data": {
      "name": "atogepant",
      "full_text": "atogepant, a calcitonin gene-related peptide (CGRP) receptor antagonist",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-09-10T12:55:00Z",
    "location_data": [
      {
        "city": "North Chicago",
        "state": "Illinois",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-09-10",
    "article_sentence": "AbbVie (NYSE: ABBV ) today announced positive topline results from the Phase 3 LUNA study, which evaluated atogepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, for the preventive treatment of menstrual migraine in adults."
  }
}

curl https://signals.autobound.ai/v1/signals/ae38799d-965f-8b6a-654e-89d847832a85 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"abbvie.com","limit":20}'